MUMBAI, India, Jan. 2 -- Intellectual Property India has published a patent application (202511102123 A) filed by Graphic Era, Dehradun, Uttarakhand, on Oct. 23, 2025, for 'a process for personalized cancer vaccine development using neoantigens.'
Inventor(s) include Deependra Pratap Singh.
The application for the patent was published on Dec. 12, under issue no. 50/2025.
According to the abstract released by the Intellectual Property India: "The present invention provides a process for personalized cancer vaccine development using neoantigens (101-106) derived from tumor-specific mutations identified via next-generation sequencing. The process integrates bioinformatics analysis (102), neoantigen prediction (103), peptide synthesis (104), vaccine formulation (105), and immune response monitoring (106). This method ensures individualized immunotherapy with enhanced precision, immune activation, and safety, enabling adaptive and efficient cancer treatment tailored to each patient's mutational landscape."
Disclaimer: Curated by HT Syndication.
